| Identification | Back Directory | [Name]
Albiglutide | [CAS]
782500-75-8 | [Synonyms]
Albugon
Gsk 716155
Naliglutide
albiglutide
Unii-5E7U48495e
Albiglutide Fragment
Albiglutide USP/EP/BP
7-36-Glucagon-like peptide I (8-glycine) (human), fusion protein with 7-36-glucagon-like peptide I (8-glycine) (human) fusion protein with serum
7-36-Glucagon-likepeptide I [8-glycine] (huMan), fusion protein with 7-36-glucagon-like peptide I[8-glycine] (huMan) fusion protein with seruM albuMin (huMan) | [Molecular Formula]
C148H223N39O46 | [MDL Number]
MFCD27976663 | [MOL File]
782500-75-8.mol | [Molecular Weight]
3284.59 |
| Hazard Information | Back Directory | [General Description]
Albiglutide (also known as naliglutide, GSK 716155) isa sequential dimer of GLP-1(7–36)(Ala8→Gly) covalentlylinked to modified human serum albumin (i.e., it is a “fusionprotein” with modified HSA). This molecule is currentlywell into phase III clinical trials. Although albiglutide,if marketed (Syncria, GlaxoSmithKline), will—likeexenatide—be administered by injection, the half-life andduration of 6 to 7 days would allow for weekly administration. | [Clinical Use]
GLP-1 receptor agonist:
Treatment of type 2 diabetes mellitus | [Enzyme inhibitor]
This GLP-1 agonist and anti?-diabetic drug? (MW = 72.9 kDa; CAS 782500-
75-8), marketed as Eperzan and Tanzeum, by GlaxoSmithKline (GSK) is
a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to
human albumin. Albiglutide has a half-life of 4-7 days, commending it for
biweekly or weekly administration in the treatment of Type 2 diabetes. The
half-life is considerably longer than exenatide (Byetta?) and liraglutide
(Victoza?). | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Albiglutide is a protein for which the expected metabolic
pathway is degradation to small peptides and individual
amino acids by ubiquitous proteolytic enzymes. |
|
|